topstockalerts
Aug 24, 8:50 PM
Veradermics shares fell to
$97.90 at midday after hitting an intraday low of
$93.81, pressured by continued insider selling and dilution concerns. The stock opened at
$101.70, near its previous close of
$102.82, before sellers regained control.
Recent SEC filings showed several large insider transactions. CEO Reid Alexander Waldman sold 67,500 shares on Aug. 17 under a prearranged Rule 10b5-1 plan, while entities linked to director John W. Childs sold 100,000 shares. Montanova Capital, affiliated with another director, sold 750,000 shares on Aug. 19, cutting its position by nearly 62%. Despite the use of prearranged plans, the concentrated selling has weighed on sentiment.
Veradermics also reported a
$23.5 million Q2 2026 net loss, up from
$15.6 million a year earlier, as clinical and operating expenses increased ahead of Phase 2/3 data for VDPHL01, its oral non-hormonal treatment for female pattern hair loss.
$MANE
